Immune/EpiCept Merge To Form Multi-Project Antibody Drug Company
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli antibody drug developer Immune Pharmaceuticals will have several projects in the pipeline, including some potential out-licensing candidates, after it makes the leap to a U.S. public company through a reverse-merger with troubled EpiCept, CEO Daniel Teper said during an interview at BIO CEO.
You may also be interested in...
Celgene’s Abraxane Scores A Win Against Tough Pancreatic Cancer
Abraxane more than doubled two-year survival and conferred a near-two-month overall survival advantage against pancreatic cancer compared with standard of care gemcitabine alone in the Phase III MPACT trial, presented Jan. 25 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco. Celgene plans global regulatory filings by mid-2013.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.